Laboratory Investigation

Kidney International (1993) 43, 1219–1225; doi:10.1038/ki.1993.172

Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression

Leslie A Bruggeman1, Jill A Pellicoro1, Elizabeth A Horigan1 and Paul E Klotman1

1Molecular Medicine Section, Laboratory of Developmental Biology, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland, USA

Correspondence: Dr Paul Klotman MD, Bldg. 30, Room 433, LDB/NIDR/NIH, 9000 Rockville Pike, Bethesda, Maryland 20892, USA.

Received 2 October 1992; Revised 25 January 1993; Accepted 28 January 1993.

Top

Abstract

Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression. Alterations in the arachidonic acid metabolites thromboxane and prostacyclin are known to contribute to hemodynamic changes observed in certain models of acute and chronic renal failure. We have previously shown that thromboxane may have an important role in mediating glomerulosclerosis by stimulating the expression of certain extracellular matrix proteins. In the present study, we compared the effects of thromboxane and prostacyclin on the expression of genes encoding basement membrane proteins using a murine teratocarcinoma cell line, that when differentiated to an endodermal phenotype synthesizes abundant extracellular matrix. Incubation of these cells with stable analogs of thromboxane and prostacyclin for four hours resulted in changes in basement membrane gene expression. Thromboxane increased steady-state mRNA levels for all three laminin chains, type IV collagen, and fibronectin, but decreased the level of mRNA for heparan sulfate proteoglycan. In contrast, incubation with carbo-prostacyclin, a stable analog of prostacyclin, decreased the steady-state mRNA level for the laminin A and B1 chains, type IV collagen and fibronectin, and increased the mRNA level for heparan sulfate proteoglycan and laminin B2. Carbo-prostacyclin did not affect cellular proliferation or thymidine incorporation. These results indicate that eicosanoids directly modulate matrix gene expression independently of hemodynamic influence, and independently of effects mediated by platelets, or mitogenesis. Furthermore, these findings suggest that the alterations in renal eicosanoid metabolism may directly participate in the pathogenesis of glomerulosclerosis and thus provide a rationale for therapy directed toward the specific inhibition of thromboxane in the treatment of progressive glomerular sclerosis.

Top

References

  1. Bolger PM, Eisner GM, Ramwell PW, Slotkoff LM: Renal actions of prostacyclin. Nature 271:467–469, 1978 | Article |
  2. Yliatalo P, Kaukinen S, Nurmi AK, Seppala E, Pessi T, Vapaatalo H: Effects of a prostacyclin analogue Iloprost on kidney function, renin-angiotensin and kallikrein-kinin systems, prostanoids and catecholamines in man. Prostaglandins 29:1063–1071, 1985
  3. Gerber JG, Nies S: The hemodynamic effects of prostaglandins in the rat. Evidence for important species variation in renovascular responses. Circ Res 44:406–410, 1979 | PubMed | ChemPort |
  4. Collins DM, Coffman TM, Klotman PE: The role of thromboxane in the pathogenesis of acute renal failure, in Acute Renal Failure, edited by Solez K, Racusen LC, New York, Marcel Dekker, Inc., 1991, pp 13–47
  5. Hamberg M, Svensson J, Wakabayashi T, Samuelsson B: Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci (USA) 71:345–349, 1974
  6. Corsini A, Folco GC, Fumagalli R, Nicosia S, Noe MA, Oliva D: (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol 90:255–261, 1987 | PubMed | ChemPort |
  7. Dutta-Roy AK, Sinha AK: Purification and properties of prostaglandin E1/prostacyclin receptor of human blood platelets. J Biol Chem 262:12685–12691, 1987 | PubMed | ChemPort |
  8. Dong YJ, Jones RL, Wilson NH: Prostaglandin E receptor subtypes in smooth muscle: Agonist activities of stable prostacyclin analogues. Br J Pharmacol 87:97–101, 1986 | PubMed | ChemPort |
  9. Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci (USA) 72:2994–2998, 1975
  10. Brazy PC, Kopp JB, Klotman PE: Glomerulosclerosis and progressive renal disease, in Contemporary Issues In Nephrology; Lipids and Renal Disease, edited by Keane WF, Stein JH, New York, Churchill Livingstone, 1991, pp 11–36
  11. Schambelan M, Blake S, Sraer J, Bens M, Nives M-P, Wahbe F: Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus. J Clin Invest 75:404–412, 1985 | PubMed | ISI | ChemPort |
  12. Bunke M, Itskovitz H: Urinary excretion and renal production of prostaglandins E2, F2alpha, and thromboxane B2 in experimental diabetes mellitus. J Lab Clin Med 108:332–339, 1986
  13. Quilley J, McGiff JC: Arachidonic acid metabolism and urinary excretion of prostaglandins and thromboxane in rats with experimental diabetes mellitus. J Pharmacol Exp Ther 234:211–216, 1985
  14. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, Fitzgerald GA: Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 77:590–594, 1986 | PubMed | ISI | ChemPort |
  15. Purkerson ML, Hoffsten PE, Klahr S: Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int 9:407–417, 1976 | PubMed | ISI | ChemPort |
  16. Okuda S, Onoyama K, Fujima S, Oh Y, Nomoto K, Omae T: Influence of hypertension on the progression of experimental autologous immune complex nephritis. J Lab Clin Med 101:461–471, 1983 | PubMed | ISI | ChemPort |
  17. Fukumoto S, Tanaka K: Protective effects of thromboxane A2 synthetase inhibitors on endotoxic shock. Prostaglandin Leuk Med 11:179–188, 1983
  18. Schreiner GF, Harris KPG, Purkerson ML, Klahr S: Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney. Kidney Int 34:487–493, 1988 | PubMed | ISI | ChemPort |
  19. Coffman TM, Yarger WE, Klotman PE: Functional role of thromboxane production by acutely rejecting renal allografts in rats. J Clin Invest 75:1242–1248, 1985 | PubMed |
  20. Scott WA, Pawlowski NA, Andreach M, Cohn ZA: Resting macrophages produce distinct metabolites from exogenous arachidonic acid. J Exp Med 155:535–547, 1982
  21. Herrmann F, Lindemann A, Gauss J, Mirtelsmann R: Cytokine-stimulation of prostaglandin synthesis from endogenous and exogenous arachidonic acids in polymorphonuclear leukocytes involving activation and new synthesis of cyclooxygenase. Eur J Immunol 20:2513–2516, 1990
  22. Petrulis AS, Aikawa M, Dunn MJ: Prostaglandin and thromboxane synthesis by rat glomerular epithelial cells. Kidney Int 20:469–474, 1981 | PubMed | ISI | ChemPort |
  23. Scharschmidt LA, Dunn MJ: Prostaglandin synthesis by rat glomerular mesangial cells in culture: Effect of angiotensin II and arginine vasopressin. J Clin Invest 71:1756–1764, 1983 | PubMed | ISI | ChemPort |
  24. Farman KN, Pradelles P, Bonvalet JP: PGE2, PGF2alpha, 6-keto-PGF1alpha and TxB2 synthesis along the rabbit nephron. Am J Physiol 252:F53–F59, 1987
  25. Sraer J, Ardaillou N, Sraer J-D, Ardaillou R: In vitro prostaglandin synthesis by human glomeruli and papillae. Prostaglandin 23:855–864, 1982
  26. Hassid A, Konieczkowski M, Dunn MJ: Prostaglandin synthesis in isolated rat kidney glomeruli. Proc Natl Acad Sci (USA) 76:1155–1159, 1979
  27. Horiguchi J, Spriggs D, Imamura K, Stone R, Luebbers R, Kufe D: Role of arachidonic acid metabolism in transcriptional induction of tumor necrosis factor gene expression by phorbol ester. Mol Cell Biol 9:252–258, 1989
  28. Varga J, Diaz-Perez A, Rosenbloom J, Jimenez SA: PGE2 causes a coordinate decrease in the steady state levels of fibronectin and type I and III procollagen mRNAs in normal human dermal fibroblasts. Biochem Biophys Res Commun 147:1282–1288, 1987 | Article | PubMed | ChemPort |
  29. Bruggeman LA, Horigan EA, Horikoshi S, Ray PE, Klotman PE: Thromboxane stimulates synthesis of extracellular matrix proteins in vitro. Am J Physiol 261:F488–F494, 1991 | PubMed | ISI | ChemPort |
  30. Strickland S, Smith KK, Marotti KR: Hormonal induction of differentiation in teratocarcinoma stem cells: Generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell 21:347–355, 1980 | Article | PubMed | ISI | ChemPort |
  31. Kleinman HK, Ebihara I, Killen PD, Sasaki M, Cannon FB, Yamada Y, Martin GR: Genes for basement membrane proteins are coordinately expressed in differentiating F9 cells but not in normal adult murine tissues. Dev Biol 122:373–378, 1987 | Article | PubMed | ChemPort |
  32. Kapoor R, Prehm P: Changes in proteoglycan composition of F9 teratocarcinoma cells upon differentiation. Eur J Biochem 137:589–595, 1983
  33. Grover A, Edwards SA, Bourdon M, Adamson ED: Proteoglycan-19, laminin and collagen type IV production is correlated with the levels of mRNA in F9 cell aggregates differentiating in the presence or absence of cyclic AMP. Differentiation 36:138–144, 1987
  34. Baldwin CT, Silbert JE, Humphries DE, Cogburn JN, Smith BD: Increased proteoglycan synthesis following the differentiation of F9 embryonal carcinoma cells: Formation of a differentiation-specific proteoheparan sulfate. Matrix 9:389–396, 1989
  35. Chomczymski P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159, 1987
  36. Sasaki M, Kleinman HK, Huber H, Deutzmann R, Yamada Y: Laminin, a multidomain protein: The A chain has a unique globular domain and homology with the basement membrane proteoglycan and the laminin B chains. J Biol Chem 263:16536–16544, 1988 | PubMed | ISI | ChemPort |
  37. Sasaki M, Kato S, Kohno K, Martin GR, Yamada Y: Sequence of the cDNA encoding the laminin B1 chain reveals a multidomain protein containing cysteine-rich repeats. Proc Natl Acad Sci (USA) 84:935–939, 1987
  38. Sasaki M, Yamada Y: The laminin B2 chain has a multidomain structure homologous to the B1 chain. J Biol Chem 262:17111–17117, 1987 | PubMed | ISI | ChemPort |
  39. Oberbaümer I, Laurent M, Schwarz U, Sakuarai Y, Yamada Y, Vogeli G, Voss T, Siebold B, Glanville RW, Künh K: Amino acid sequence of the non-collagenous globular domain (NC1) of the alpha1(IV) chain basement membrane collagen as derived from complementary DNA. Eur J Biochem 147:217–224, 1985 | Article | PubMed | ISI | ChemPort |
  40. Noonan DM, Horigan EA, Ledbetter SR, Vogeli G, Sasaki M, Yamada Y, Hassell JR: Identification of cDNA clones encoding different domains of the basement membrane heparan sulfate proteoglycan. J Biol Chem 263:16379–16387, 1988
  41. Kornblihtt AR, Umezawa K, Vibe-Pedersen K, Baralle FE: Primary structure of human fibronectin: Differential splicing may generate at least ten polypeptides from a single gene. EMBO J 4:1755–1759, 1985 | PubMed | ISI | ChemPort |
  42. Ardaillou N, Nivez M-P, Bellon G, Combe C, Ardaillou R: Effect of prostaglandin E2 on proline uptake and protein synthesis by cultured human mesangial cells. Kidney Int 38:1151, 1990 | Article | PubMed |
  43. Ardaillou N, Hagege J, Nives M-P, Ardaillou R, Schlondorff D: Vasoconstrictor-evoked prostaglandin synthesis in cultured human mesangial cells. Am J Physiol 248:F240–F246, 1985 | PubMed |
  44. Stahl RAK, Paravicini M, Schollmeyer P: Angiotensin II stimulation of prostaglandin E2 and 6-keto-F1alpha formation by isolated human glomeruli. Kidney Int 26:30–34, 1984 | PubMed | ISI | ChemPort |
  45. Nerlich A, Schleicher E: Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 139:889–899, 1991 | PubMed | ISI | ChemPort |
  46. Klein DJ, Oegema TR, Brown DM: Release of glomerular heparan-35SO4 proteoglycan by heparin from glomeruli of strepto-zocin-induced diabetic rats. Diabetes 38:130–139, 1989 | PubMed | ISI | ChemPort |
  47. Shimomura H, Spiro RG: Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36:374–381, 1987
  48. Klein DJ, Brown DM, Oegema TR: Glomerular proteoglycans in diabetes. Partial structural characterization and metabolism of de novo synthesized heparan-35SO4 and dermatan-35SO4 proteoglycans in streptozocin-induced diabetic rats. Diabetes 35:1130–1142, 1986 | PubMed | ISI | ChemPort |
  49. Rohrbach DH, Wagner CW, Star VL, Martin GR, Brown KS, Yoon JW: Reduced synthesis of basement membrane heparan sulfate proteoglycan in streptozotocin-induced diabetic mice. J Biol Chem 258:11672–11677, 1983 | PubMed | ChemPort |
  50. Fukui M: Altered glomerular mRNA expression of basement membrane components and type I collagen in diabetic rats treated with or without insulin therapy. Nippon Jinzo Gakkai Shi 33:275–281, 1991
  51. Ledbetter S, Copeland EJ, Noonan D, Vogeli G, Hassell JR: Altered steady state mRNA levels of basement membrane proteins in diabetic mouse kidneys and thromboxane synthase inhibition. Diabetes 39:196–203, 1990 | PubMed | ISI | ChemPort |
  52. Poulsom R, Kurkinen M, Prockop DJ, Boot-Handford RP: Increased steady-state levels of laminin B1 mRNA in kidneys of long-term streptozotocin-diabetic rats. J Biol Chem 263:10072–10076, 1988 | PubMed | ISI | ChemPort |
  53. Craven PA, Caines MA, DeRubertis FR: Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to hyperfiltration of early diabetes. Metabolism 36:95–103, 1987 | Article | PubMed | ChemPort |
  54. Datar S, McCauley FA, Wilson TW: Testing the "redirectional hypothesis" of prostaglandin metabolism in the kidney. Prostaglandins 33:275–285, 1987
  55. Parry MJ, Randall MJ, Hawkeswood E, Cross PE, Dickinson RP: Enhanced production of prostacyclin in blood after treatment with selective thromboxane synthetase inhibitor, UK-38,485. Br J Pharmacol 77:547, 1982

Extra navigation

.
ADVERTISEMENT